HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1 | Zendy

Jeffrey M. Venstrom | Zendy; Gianfranco Pittari | Zendy; Ted Gooley | Zendy; Joseph H. Chewning | Zendy; Stephen R. Spellman | Zendy; Michael Haagenson | Zendy; Meighan M. Gallagher | Zendy; Mari Malkki | Zendy; Effie W. Petersdorf | Zendy; Bo Dupont | Zendy; Katharine C. Hsu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1

Author(s) -

Jeffrey M. Venstrom,

Gianfranco Pittari,

Ted Gooley,

Joseph H. Chewning,

Stephen R. Spellman,

Michael Haagenson,

Meighan M. Gallagher,

Mari Malkki,

Effie W. Petersdorf,

Bo Dupont,

Katharine C. Hsu

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1200503

Subject(s) - immunology , human leukocyte antigen , medicine , hazard ratio , hematopoietic stem cell transplantation , myeloid leukemia , transplantation , genotyping , leukemia , antigen , genotype , biology , confidence interval , genetics , gene

Of the cancers treated with allogeneic hematopoietic stem-cell transplantation (HSCT), acute myeloid leukemia (AML) is most sensitive to natural killer (NK)-cell reactivity. The activating killer-cell immunoglobulin-like receptor (KIR) 2DS1 has ligand specificity for HLA-C2 antigens and activates NK cells in an HLA-dependent manner. Donor-derived NK reactivity controlled by KIR2DS1 and HLA could have beneficial effects in patients with AML who undergo allogeneic HSCT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research